Harrow acquires global rights to TYRVAYA nasal spray for dry eye disease from Viatris for up to $100M

HARROW, INC.

$30M cash at closing plus up to $70M in contingent milestone payments tied to TYRVAYA net sales.
TYRVAYA is first and only FDA-approved nasal spray for dry eye disease; approved in US, China, Taiwan.
Complements Harrow's VEVYE franchise with different mechanism (stimulates basal tear production vs anti-inflammatory).
Expected to close in H2 2026, subject to customary closing conditions.
Harrow expects to fund upfront cash payment from cash on hand.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.